Novo Nordisk wins design award for twistable needle
BAGSV?RD, Denmark Novo Nordisk has taken home an award for the design of one of its needles, the Danish drug maker announced.
Novo Nordisk won the Japan Industrial Design Promotion Organization’s Good Design Award in the “Society – Medical Equipment” category for NovoTwist, a new needle designed for use with the FlexPen insulin pen. The needle has a twistable attachment designed to make injection easier for diabetes patients.
The organization chose the NovoTwist from almost 3,000 entries. Previous award winners of the award, also known as the G-Mark Award, have included Apple, Toshiba, Toyota and Nintendo. Novo Nordisk won the same award in 2005 for the NovoPen 4.
Pleio’s medication adherence program yields positive results
PHILADELPHIA A company that runs a medication adherence program said its program had a “highly significant” effect.
Pleio Health Support Systems announced Monday results of the Pleio GoodStart program, analyzing data from 1,776 patients taking a chronic cardiovascular medication between May 2008 and 2009 that showed patients refilled an average of two additional 30-day prescriptions during their initial nine-month period of taking the medication.
Patients in the GoodStart program also refilled their prescriptions an average of 10 days sooner than those in the control group, Pleio said.
Deloitte report: Pharmaceutical companies’ ‘patent cliff’ could bolster mergers, acquisitions
NEW YORK A wave of acquisitions indicates a trend of consolidation in the drug industry, as companies seek ways to build up their research and development pipelines while reducing overhead costs, according to a report released Tuesday by professional services firm Deloitte.
One of the factors driving mergers is that drugs representing more than $74 billion in sales will lose patent protection by 2012, which many analysts have come to call the “patent cliff.”
“With so many rapidly changing dynamics – the patent cliff, healthcare reform and still-dry capital markets – the trends in life sciences industry consolidation are almost certain to continue with a growing emphasis on those deals with companies involved with late-stage developed compounds,” Deloitte & Touche partner Phil Pfrang said in a statement. “Healthy companies have good cause to pursue deals that promise faster revenue streams and profits.”